Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003580 · ClinicalTrials.gov registry record · Phase 2
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
A Phase 2 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003580: Completed Phase 2 study, sponsored by University of Tennessee.
NCT00003580 is a Phase 2 study that has completed, run by University of Tennessee. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003580, a Phase 2 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating side effects of treatment in patients receiving radiation therapy and cisplatin for advanced head and neck cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00003580 record still lists
NCT00003580 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003580 about?
NCT00003580 is a clinical study titled "Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PUR...
What is the current status of trial NCT00003580?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-06. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00003580?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003580?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia